35.00
3.52 (11.18%)
| Penutupan Terdahulu | 31.48 |
| Buka | 32.26 |
| Jumlah Dagangan | 4,166,892 |
| Purata Dagangan (3B) | 1,617,176 |
| Modal Pasaran | 6,441,014,784 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.00 |
| Harga / Jualan (P/S) | 9.67 |
| Harga / Buku (P/B) | 5.85 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -28.22% |
| Margin Operasi (TTM) | -40.19% |
| EPS Cair (TTM) | -0.960 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 134.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 33.69% |
| Nisbah Semasa (MRQ) | 4.62 |
| Aliran Tunai Operasi (OCF TTM) | -144.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -38.58 M |
| Pulangan Atas Aset (ROA TTM) | -10.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -15.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Legend Biotech Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.33% |
| % Dimiliki oleh Institusi | 55.58% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 84.00 (RBC Capital, 140.00%) | Beli |
| Median | 75.00 (114.29%) | |
| Rendah | 55.00 (Cantor Fitzgerald, 57.14%) | Beli |
| Purata | 73.00 (108.57%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 32.30 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 55.00 (57.14%) | Beli | 27.80 |
| Truist Securities | 14 May 2025 | 71.00 (102.86%) | Beli | 27.80 |
| RBC Capital | 22 Apr 2025 | 84.00 (140.00%) | Beli | 34.48 |
| HC Wainwright & Co. | 16 Apr 2025 | 75.00 (114.29%) | Beli | 33.46 |
| 08 Apr 2025 | 75.00 (114.29%) | Beli | 30.77 | |
| Morgan Stanley | 17 Mar 2025 | 80.00 (128.57%) | Beli | 37.94 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Jun 2025 | Pengumuman | Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting |
| 22 May 2025 | Pengumuman | Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT |
| 22 May 2025 | Pengumuman | Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT |
| 19 May 2025 | Pengumuman | Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 13 May 2025 | Pengumuman | Legend Biotech Reports First Quarter 2025 Results and Recent Highlights |
| 29 Apr 2025 | Pengumuman | Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |